A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-1)
The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must have a diagnosis of Crohn's Disease (CD) for at least 3 months prior to baseline
Participants must have a confirmed diagnosis of moderate to severe CD
Participants must have demonstrated intolerance, loss of response or inadequate response to conventional or to biologic therapy for CD
Participants must, if female, meet the contraception recommendations
Participants Must Not:
Participants must not have a current diagnosis of ulcerative colitis, inflammatory bowel disease-unclassified (IBD-U) (formerly known as indeterminate colitis) or short bowel syndrome
Participants must not have a stoma, ileoanal pouch or ostomy
Participants must not have had a bowel resection within 6 months, or any kind of intra-abdominal or extra abdominal surgery within 3 months of baseline
Participants must not have ever received any monoclonal antibodies binding IL-23
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo